Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment

Nature Nanotechnology

Volumn 6, Issue 9, 2011, Pages 594-602

  Mikhaylov, Georgy ^a   Mikac, Ursa ^a,b   Magaeva, Anna A ^c   Itin, Volya I ^c   Naiden, Evgeniy P ^c   Psakhye, Ivan ^a,k   Babes, Liane ^d   Reinheckel, Thomas ^d   Peters, Christoph ^d   Zeiser, Robert ^e   Bogyo, Matthew ^f   Turk, Vito ^a,g   Psakhye, Sergey G ^c,h   Turk, Boris ^a,g,i,j   Vasiljeva, Olga ^a  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b EN FIST CENTRE OF EXCELLENCE   (Slovenia)

^c TOMSK SCIENTIFIC CENTER   (Russian Federation)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Center of Excellence CIPKEBIP   (Slovenia)

^h INSTITUTE OF STRENGTH PHYSICS AND MATERIALS SCIENCE   (Russian Federation)

ⁱ UNIVERSITY OF LJUBLJANA   (Slovenia)

^j Center of Excellence Nanosciences and Nanotechnology   (Slovenia)

^k MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; DISEASES; LIPOSOMES; NANOMAGNETICS; NANOPARTICLES; TUMORS;

CANCER CELLS; DRUG DELIVERY SYSTEM; MAGNETIC NANO-PARTICLES; MICROENVIRONMENTS; PROTEASE INHIBITOR; STROMAL CELLS; SYSTEMIC DELIVERIES; TUMOUR PROGRESSION;

TARGETED DRUG DELIVERY;

CYSTEINE PROTEINASE INHIBITOR; DOXORUBICIN; FERRI LIPOSOME; JPM 565; LIPOSOME; LUCIFERIN; MACROGOL; MAGNETIC NANOPARTICLE; MAGNETITE; NANOCARRIER; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; ATOMIC FORCE MICROSCOPY; BREAST TUMOR; CANCER INHIBITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; IN VIVO STUDY; INTERNALIZATION; MOUSE; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN DEGRADATION; STROMA CELL; TARGET CELL DESTRUCTION; TRANSGENIC MOUSE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME;

EID: 80052587306     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2011.112     Document Type: Article

References (48)

1. Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour-host interface. Nature 411, 375-379 (2001).
2. Mueller, M. M. & Fusenig, N. E. Friends or foes-bipolar effects of the tumour stroma in cancer. Nature Rev. Cancer 4, 839-849 (2004).
3. Santos, A. M., Jung, J., Aziz, N., Kissil, J. L. & Puré, E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 119, 3613-3625 (2009).
4. Rosi, N. L. & Mirkin, C. A. Nanostructures in biodiagnostics. Chem. Rev. 105, 1547-1562 (2005).
5. Arrueboa, M., Fernańdez-Pachecoa, R., Ibarraa, M. R. & Santamariá, S. Magnetic nanoparticles for drug delivery. Nanotoday 2, 22-32 (2007).
6. Galanzha, E. I. et al. In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nature Nanotech. 4, 855-860 (2009).
7. Namiki, Y. et al. A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery. Nature Nanotech. 4, 598-606 (2009).
8. Kim, J.W., Galanzha, E. I., Shashkov, E. V., Moon, H. M. & Zharov, V. P. Golden carbon nanotubes as multimodal photoacoustic and photothermal high-contrast molecular agents. Nature Nanotech. 4, 688-694 (2009).
9. Vlaskou, D. et al. Magnetic and acoustically active lipospheres for magnetically targeted nucleic acid delivery. Adv. Funct. Mater. 20, 3881-3894 (2010).
10. Bulte, J. W. M. et al. Selective Mr imaging of labeled human peripheral-blood mononuclear-cells by liposome mediated incorporation of dextran-magnetite particles. Magn. Reson. Med. 29, 32-37 (1993).
11. Bulte, J.W., de Cuyper, M., Despres, D. & Frank, J. A. Short- vs. long-circulating magnetoliposomes as bone marrow-seeking MR contrast agents. J. Magn. Reson. Imaging 9, 329-335 (1999).
12. Bulte, J. W. M., de Cuyper, M., Despres, D. & Frank, J. A. Preparation, relaxometry, and biokinetics of PEGylated magnetoliposomes as MR contrast agent. J. Magn. Magn. Mater. 194, 204-209 (1999).
13. Lee, J. et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nature Med. 13, 95-99 (2007).
14. Torchilin, V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm. 71, 431-444 (2009).
15. Medarova, Z., Pham, W., Farrar, C., Petkova, V. & Moore, A. In vivo imaging of siRNA delivery and silencing in tumors. Nature Med. 13, 372-377 (2007).
16. Naiden, E. et al. Magnftis pdopfrtifs and stdustural parameters of nanosizfd owidf ffrrimagnft powdfrs produsfd bymfshanoshemisal synthfsis frpm salt solutions. Phys. Solid State 5, 891-900 (2003).
17. Bogdanov, A. A., Martin, C., Weissleder, R. & Brady, T. J. Trapping of dextrancoated colloids in liposomes by transient binding to aminophospholipid- preparation of ferrosomes. Biochim. Biophys. Acta Biomembranes 1193, 212-218 (1994).
18. Di Paolo, D. et al. Liposome-mediated therapy of neuroblastoma. Methods Enzymol. 465, 225-249 (2009).
19. Torchilin, V. P. et al. Poly(ethylene glycol) on the liposome surface - on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta Biomembranes 1195, 11-20 (1994).
20. Fortin-Ripoche, J. P. et al. Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: Feasibility. Radiology 239, 415-424 (2005).
21. Martina, M. S. et al. Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J. Am. Chem. Soc. 127, 10676-10685 (2005).
22. Stollfuss, J. C. et al. Rectal carcinoma: High-spatial-resolution MR imaging and T2 quantification in rectal cancer specimens. Radiology 241, 132-141 (2006).
23. Seo, W. S. et al. FeCo/graphitic-shell nanocrystals as advanced magneticresonance- imaging and near-infrared agents. Nature Mater. 5, 971-976 (2006).
24. Ai, H. et al. Magnetite-loaded polymeric micelles as ultrasensitive magneticresonance probes. Adv. Mater. 17, 1949-1952 (2005).
25. Shapiro, M. G., Atanasijevic, T., Faas, H., Westmeyer, G. G. & Jasanoff, A. Dynamic imaging with MRI contrast agents: Quantitative considerations. Magn. Reson. Imaging 24, 449-462 (2006).
26. Na, H. B. et al. Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem. Int. Ed. 46, 5397-5401 (2007).
27. Zhao, M., Josephson, L., Tang, Y. &Weissleder, R. Magnetic sensors for protease assays. Angew Chem. Int. Ed. 42, 1375-1378 (2003).
28. Atanasijevic, T., Shusteff, M., Fam, P. & Jasanoff, A. Calcium-sensitive MRI contrast agents based on superparamagnetic iron oxide nanoparticles and calmodulin. Proc. Natl Acad. Sci. USA 103, 14707-14712 (2006).
29. Guy, C. T., Cardiff, R. D. & Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol. Cell Biol. 12, 954-961 (1992).
30. Wender, P. A. et al. Real-time analysis of uptake and bioactivatable cleavage of luciferin-transporter conjugates in transgenic reporter mice. Proc. Natl Acad. Sci. USA 104, 10340-10345 (2007).
31. Greenbaum, D., Medzihradszky, K. F., Burlingame, A. & Bogyo, M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem. Biol. 7, 569-581 (2000).
32. Greenbaum, D. et al. Chemical approaches for functionally probing the proteome. Mol. Cell Proteomics 1, 60-68 (2002).
33. Joyce, J. A. et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 443-453 (2004).
34. Bell-McGuinn, K., Garfall, A., Bogyo, M., Hanahan, D. & Joyce, J. A. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 67, 7378-7385 (2007).
35. Schurigt, U. et al. Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol. Chem. 389, 1067-1074 (2008).
36. Vasiljeva, O. et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 66, 5242-5250 (2006).
37. Vasiljeva, O. & Turk, B. Dual contrasting roles of cysteine cathepsins in cancer progression: Apoptosis versus tumour invasion. Biochimie 90, 380-386 (2008).
38. Sevenich, L. et al. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc. Natl Acad. Sci. USA 107, 2497-2502 (2010).
39. Gocheva, V. & Joyce, J. A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6, 60-64 (2007).
40. Turk, V., Kos, J. & Turk, B. Cysteine cathepsins (proteases)-on the main stage of cancer? Cancer Cell 5, 409-410 (2004).
41. Rossi, A., Deveraux, Q., Turk, B. & Sali, A. Comprehensive search for cysteine cathepsins in the human genome. Biol. Chem. 385, 363-372 (2004).
42. Mohamed, M. M. & Sloane, B. F. Cysteine cathepsins: Multifunctional enzymes in cancer. Nature Rev. Cancer 6, 764-775 (2006).
43. Vasiljeva, O. et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 13, 387-403 (2007).
44. Sloane, B. F. et al. Cathepsin B and tumor proteolysis: Contribution of the tumor microenvironment. Semin. Cancer Biol. 15, 149-157 (2005).
45. Gocheva, V. et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 24, 241-255 (2010).
46. Ceelen, W. P. & Flessner, M. F. Intraperitoneal therapy for peritoneal tumors: Biophysics and clinical evidence. Nature Rev. Clin. Oncol. 7, 108-115 (2010).
47. Sadaghiani, A. M. et al. Design, synthesis, and evaluation of in vivo potency and selectivity of epoxysuccinyl-based inhibitors of papain-family cysteine proteases. Chem. Biol. 14, 499-511 (2007).
48. Vasiljeva, O. et al. Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 27, 4191-4199 (2008).